These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17291359)

  • 1. Randomization and baseline transmission in vaccine field trials.
    Struchiner CJ; Halloran ME
    Epidemiol Infect; 2007 Feb; 135(2):181-94. PubMed ID: 17291359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency of estimating vaccine efficacy for susceptibility and infectiousness: randomization by individual versus household.
    Datta S; Halloran ME; Longini IM
    Biometrics; 1999 Sep; 55(3):792-8. PubMed ID: 11315008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Spatial heterogeneity of environmental risk in randomized prevention trials: consequences and modeling".
    Guindo A; Sagara I; Ouedraogo B; Sallah K; Assadou MH; Healy S; Duffy P; Doumbo OK; Dicko A; Giorgi R; Gaudart J
    BMC Med Res Methodol; 2019 Jul; 19(1):149. PubMed ID: 31307393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous Inference of Treatment Effect Modification by Intermediate Response Endpoint Principal Strata with Application to Vaccine Trials.
    Zhuang Y; Huang Y; Gilbert PB
    Int J Biostat; 2019 Jul; 16(1):. PubMed ID: 31265429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological factors in clinical trial design.
    Wassilak S
    Dev Biol Stand; 1998; 95():75-83. PubMed ID: 9855417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmented designs to assess immune response in vaccine trials.
    Follmann D
    Biometrics; 2006 Dec; 62(4):1161-9. PubMed ID: 17156291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms.
    España G; Hogea C; Guignard A; Ten Bosch QA; Morrison AC; Smith DL; Scott TW; Schmidt A; Perkins TA
    PLoS One; 2019; 14(1):e0210041. PubMed ID: 30682037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.
    Kahn R; Hitchings M; Bellan S; Lipsitch M
    Clin Trials; 2018 Apr; 15(2):207-211. PubMed ID: 29374974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials.
    Chung S; Ben-Menachem E; Sperling MR; Rosenfeld W; Fountain NB; Benbadis S; Hebert D; Isojärvi J; Doty P
    CNS Drugs; 2010 Dec; 24(12):1041-54. PubMed ID: 21090838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated.
    Follmann D; Fintzi J; Fay MP; Janes HE; Baden LR; El Sahly HM; Fleming TR; Mehrotra DV; Carpp LN; Juraska M; Benkeser D; Donnell D; Fong Y; Han S; Hirsch I; Huang Y; Huang Y; Hyrien O; Luedtke A; Carone M; Nason M; Vandebosch A; Zhou H; Cho I; Gabriel E; Kublin JG; Cohen MS; Corey L; Gilbert PB; Neuzil KM
    Ann Intern Med; 2021 Aug; 174(8):1118-1125. PubMed ID: 33844575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linear and loglinear structural mean models to evaluate the benefits of an on-demand dosing regimen.
    Comté L; Vansteelandt S; Tousset E; Baxter G; Vrijens B
    Clin Trials; 2009 Oct; 6(5):403-15. PubMed ID: 19737849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.